NEW YORK (GenomeWeb News) – Diagnostics developer Asuragen said today that is has received accreditation as a CLIA-compliant lab by the College of American Pathologists (CAP).

The Austin, Texas-based firm said that the CAP accreditation is "a crucial step" in its plans to begin commercializing its miRNA-based oncology and clinical sample testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.